Campbell Shannon
SEC insider (Form 3/4/5 filer). CIK 0002018966. Director at Black Diamond Therapeutics, Inc. (BDTX) and 1 other issuer. 5 reported Form 4/5 transactions since Sep 2024; latest on Jun 26, 2026. Located in CAMBRIDGE, MA.
Companies Campbell Shannon has filed insider reports for
- Black Diamond Therapeutics, Inc. (BDTX): Director
- Zentalis Pharmaceuticals, Inc. (ZNTL): Director
Campbell Shannon
CIK: 0002018966
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 26, 2026BDTX
Black Diamond Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
40K shares- - May 26, 2026ZNTL
Zentalis Pharmaceuticals, Inc.
AwardDirect114.2K shares- - Jun 12, 2025BDTX
Black Diamond Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
30.6K shares- - Dec 13, 2024BDTX
Black Diamond Therapeutics, Inc.
AwardDirect4.5K shares at avg. $2.50$11K - Sep 20, 2024BDTX
Black Diamond Therapeutics, Inc.
AwardDirect2.4K shares at avg. $4.78$11K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 26, 2026 |  BDTX Black Diamond Therapeutics, Inc. | Award Stock Option (Right to Buy) | 40,000 | - | - | Direct |
| May 26, 2026 |  ZNTL Zentalis Pharmaceuticals, Inc. | Award | 114,200 | - | $0 | Direct |
| Jun 12, 2025 | BDTX Black Diamond Therapeutics, Inc. | Award Stock Option (Right to Buy) | 30,550 | - | - | Direct |
| Dec 13, 2024 | BDTX Black Diamond Therapeutics, Inc. | Award | 4,500 | $2.50 | $11,250 | Direct |
| Sep 20, 2024 | BDTX Black Diamond Therapeutics, Inc. | Award | 2,354 | $4.78 | $11,252 | Direct |
1-5 of 5 transactions